STEVENSON, Md., March 21, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company") (Nasdaq:GALE) common stock during the period between November 6, 2013 and February 14, 2014, inclusive (the "Class Period").
If you have suffered a net loss from investment in Galena common stock purchased on or after November 6, 2013 and held through the revelation of negative information during and/or at the end of the Class Period, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or financial obligation, click here: http://www.browerpiven.com/securitiesfraudcases.html.
You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Attorneys at Brower Piven together have more than a century of experience litigating securities and other class action cases.
No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than May 5, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that to boost its stock price, the Company engaged in a misleading brand awareness campaign, including hiring investor relations firm The DreamTeam Group ("DreamTeam") to publish articles under aliases promoting the Company's stock without disclosing who paid for them. According to the complaint, following the February 12, 2014, publication of an article by Adam Feuerstein on TheStreet.com disclosing allegations of Galena's misleading brand awareness campaign and the Company's February 14, 2014 acknowledgment that the Company had indeed engaged DreamTeam, the value of Galena shares declined significantly.
If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.